A new generation of Immunotherapy

With multiple FDA clinical trials underway, Diakonos Research is redefining the potential of cancer immunotherapy. Studied both in the lab and in the clinical setting, Diakonos has developed revolutionary approaches to Cancer Immunotherapy that have the ability to address a variety of cancer types.

Unwavering Commitment to Science

Based in the Houston Medical Center, the sole focus of Diakonos is leveraging the body's natural capability of eliminating cancer. Using your immune system combined with our patented treatments, Diakonos has repeatedly demonstrated the ability to activate an immune attack against cancer.

Years of research at established institutions of academic excellence have led to dozens of peer-reviewed publications, patents, out-licenses, FDA clinical trials, and a wealth of opportunities moving forward.

It’s simple – Where biology leads, we follow.

Unlocking the Potential
‍of the Immune System


Diakonos has discovered three separate immunotherapy protocols that take advantage of the immune system's ability to target and fight cancer.

Multiple clinical trials are underway to further validate these approaches to cancer treatment.

Learn more about our science

Driven by Innovation

Dendritic Cell Vaccine. Dendritic Cells represent one of the most underutilized cells in Immunotherapy. With the patented Diakonos approach to activating patient's Dendritic Cells, a complete and aggressive immune response is initiated against solid tumors.
Intratumoral Injection. Leveraging a patented intratumoral injection, Diakonos has demonstrated an ability to disrupt the Tumor Microenvironment, destroy tumor cells, and stimulate an immune response against the tumor. Pending final licensing.
CAR T cell Vehicle. In creating a powerful TH1 immune response with our patented Dendritic Cell protocol, the Diakonos team discovered the robust and durable effectiveness of a unique population of responding CD8 T cells. Pending final licensing.

Interested in learning more about the Diakonos science or clinical trials?

Our team looks forward to working with clinicians in either exploring new trials or helping patients participate in one of our existing trials.

Contact Us

Clinical Trials Underway

Diakonos currently has multiple clinical trials underway for the treatment of Pancreatic Adenocarcinoma, Glioblastoma, and Sarcoma (Pending). If you would like to participate in these trials, please contact us today.

Pancreatic Adenocarcinoma
Baylor College of Medicine
Phase 1, NCT04157127

Conducted in partnership with the Baylor College of Medicine, this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous Dendritic Cells (DCs) to Pancreatic Cancer patients as adjuvant therapy following completion of standard chemotherapy.

Glioblastoma
MD Anderson Cooper, UT Health Science Center
Phase 1, NCT04552886

Conducted in partnership with the MD Anderson Cooper Hospital, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Glioblastoma (GBM) after undergoing neurosurgical tumor resection, and in whom a neuropathological diagnosis has been established.

Sarcoma
‍MD Anderson
Phase 1, Pending

Conducted in partnership with the MD Anderson, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Sarcoma after undergoing Standard of Care.